.jpg)
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a leading player in the field of clinical-stage biopharmaceuticals, is thrilled to announce a groundbreaking collaboration with Ionis Pharmaceuticals, Inc. The common goal? To discover, develop, and commercialize a pioneering antisense oligonucleotide (ASO) therapy for an undiagnosed severe chronic kidney ailment.
The Power of Collaboration
This collaboration brings together the best of both worlds. Chinook's precision medicine approach and deep understanding of nephrology, combined with Ionis' broad expertise in RNA-targeted therapeutics, will create a potent force for innovation and medical breakthroughs.
"Our collaboration with Ionis strengthens our position as the leading kidney disease company and allows us to target critical genetic and molecular drivers," says Dr. Andrew King, Chief Scientific Officer of Chinook.
The Roadmap
Under the terms of this collaboration, Chinook will make an undisclosed upfront payment to Ionis, with potential for further development and regulatory milestone payments, as well as royalties. Ionis will spearhead IND-enabling toxicology studies, while Chinook will handle clinical development and commercialization.
The Potential of Antisense Technology
Antisense therapies are designed to locate, bind to, and destroy mRNA in a highly specific manner, dramatically reducing the amount of disease-causing protein. They can also treat diseases caused by protein deficiency by increasing protein production and restoring it to normal levels.
A Glimpse Into Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops precision medicines for kidney diseases. Their product candidates are being explored in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways.
The Leading Programs
Chinook's flagship program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is in phase 1 development.
The Future
Chinook's research and discovery efforts are focused on building a pipeline of precision medicines for rare, severe chronic kidney diseases with defined genetic and molecular drivers. Leveraging insights from kidney single cell RNA sequencing and large CKD patient cohorts that have been comprehensively phenotyped, with retained biosamples and prospective clinical follow-up, the aim is to discover and develop therapeutic candidates with mechanisms of action targeted against key kidney disease pathways.
Indications and Targets
The primary indications for these treatments include kidney diseases, glomerular disease, glomerulonephritis, and IgA. The major targets are the endothelin receptor and LDHA.
Conclusion
This collaboration between Chinook Therapeutics and Ionis Pharmaceuticals has immense potential to advance the treatment of rare, severe chronic kidney diseases. With the power of antisense technology and the expertise of both companies, the future looks promising for patients living with kidney disease.
Accelerate your strategic R&D decision-making with Synapse, PatSnap's AI-powered Connected Innovation Intelligence Platform for Life Sciences Professionals.
Disclaimer: The content in this article is sourced from reliable networks. However, if any infringement is spotted, please contact us for modifications.
Comments